Mutation profile of BBS genes in Iranian patients with Bardet-Biedl syndrome: genetic characterization and report of nine novel mutations in five BBS genes.

Bardet-Biedl syndrome (BBS) is a rare ciliopathy disorder that is clinically and genetically heterogeneous with 18 known genes. This study was performed to characterize responsible genes and mutation spectrum in a cohort of 14 Iranian families with BBS. Sanger sequencing of the most commonly mutated genes (BBS1, BBS2 and BBS10) accounting for ∼50% of BBS patients determined mutations only in BBS2, including three novel mutations. Next, three of the remaining patients were subjected to whole exome sequencing with 96% at 20 × depth of coverage that revealed novel BBS4 mutation. Observation of no mutation in the other patients represents the possible presence of novel genes. Screening of the remaining patients for six other genes (BBS3, BBS4, BBS6, BBS7, BBS9 and BBS12) revealed five novel mutations. This result represents another indication for the genetic heterogeneity of BBS and extends the mutational spectrum of the disease by introducing nine novel mutations in five BBS genes. In conclusion, although BBS1 and BBS10 are among the most commonly mutated genes in other populations like Caucasian, these two seem not to have an important role in Iranian patients. This suggests that a different strategy in molecular genetics diagnostic approaches in Middle Eastern countries such as Iran should be considered.

Gene Panel Testing in Hereditary Breast Cancer.

BACKGROUND: Breast cancer (BC) is a highly complex, heterogeneous and multifactorial disease and is the most commonly diagnosed cancer and the leading cause of cancer-related mortality in women worldwide. Family history and genetic mutations are important risk factors for BC. While studies in twins have estimated that about 10%-30% of BC are due to hereditary factors, only 4%-5% of them are due to mutations in BRCA1 or BRCA2 genes. Our aim was to investigate the role of other BC genes in familial BC among the Iranian population. METHODS: We selected 61 BC patients who were wild-type for BRCA1 and BRCA2 mutations but who met the criteria for hereditary BC based on the American College of Medical Genetics and Genomics (ACMG) and the National Comprehensive Cancer Network (NCCN) guidelines. We performed targeted sequencing covering the exons of 130 known cancer susceptibility genes based on the Cancer Gene Census list. RESULTS: We found seven mutations in seven known BC susceptibility genes (RAD50, PTEN, TP53, POLH, DKC1, WRN and CHEK2) in seven patients including two pathogenic frameshift variants in RAD50 and WRN genes, four pathogenic missense variants in TP53, PTEN, POLH, and DKC1 genes and a pathogenic splice donor variant in the CHEK2 gene. The presence of all these variants was confirmed by Sanger sequencing and Gap reverse transcription-polymerase chain reaction (RT-PCR) for the splice variant. In silico analysis of all of these variants predicted them to be pathogenic. CONCLUSION: Panel testing of BC patients who met the established criteria for hereditary BC but who were negative for BRCA1/2 mutations provided additional relevant clinical information for approximately 11.5% of the families. Our findings indicate that next generation sequencing (NGS) is a powerful tool to investigative putative mutagenic variants among patients who meet the criteria for hereditary BC, but with negative results on BRCA1/2 testing.

GABAB receptors within the ventral tegmental area are involved in the expression and acquisition of morphine-induced place preference in morphine-sensitized rats.

The influence of intra-ventral tegmental area administration of gamma-amino-butyric-acid-B (GABAB) receptor agonist and antagonist on the expression and acquisition of morphine-induced conditioned place preference (CPP) in morphine-sensitized female rats was examined. Our pilot experiment showed that subcutaneous administration of morphine-(2.5, 5 and 7.5 mg/kg) induced CPP. Administration of one dose daily morphine (5 mg/kg) for 3 days followed by 5 days rest, enhanced the conditioning induced by ineffective doses of morphine (0.25, 0.5 and 1 mg/kg). Injections of GABAB receptor agonist, baclofen, (1.5 and 12 microg/rat) reduced the expression of morphine CPP whereas the dose of 6 microg/rat of the drug increased it. Baclofen also significantly reduced the acquisition of morphine CPP in morphine-sensitized animals. Administration of GABAB receptor antagonist, CGP 35348, significantly reduced the expression (12 microg/rat) and acquisition (1.5, 6 and 12 microg/rat) of morphine CPP in morphine-sensitized animals. In conclusion, results confirmed the importance of GABAB receptors within the ventral tegmental area of morphine CPP in morphine-sensitized female rats.

Chromosomal aberrations in pregnancy and fetal loss: Insight on the effect of consanguinity, review of 1625 cases.

BACKGROUND: Pregnancy loss affects 10%-15% of pregnancies and is caused by several factors, maternal and fetal. Most common cause is chromosomal aneuploidy and has traditionally been detected by karyotyping product of conception and/or fetal tissue. In recent years, array comparative genomic hybridization (a-CGH) has been used because of its higher detection and lower failure rates. METHODS: DNA was extracted from 1625 products of abortion or fetal tissue. In 1,104 cases both quantitative fluorescent-polymerase chain reaction (QF-PCR) and a-CGH, and in 521 cases only a-CGH, was performed. RESULTS: The detection rate using QF-PCR and a-CGH is 20% compared to 12.7%, overall, and 15.7%, excluding failed samples, by karyotypes in our center. QF-PCR and a-CGH failed in 1.9% of cases, while the failure rate for karyotypes was 20.1%. The difference of detection and failure rates is significant (p-value < 0.001 and p-value < 0.001 respectively). Unexpectedly we also found a significant difference in frequency of imbalances in related versus unrelated couples. (χ2  = 11.4926, p-value < 0.001). CONCLUSION: It is highly likely that the pregnancy loss in consanguineous couples is caused by other genetic and immune mechanisms. It is plausible that, through the same mechanism by which single gene disorders have a higher prevalence of manifesting disease in consanguineous couples, they can cause lethal genetic disorders leading to pregnancy loss and intra-uterine fetal death (IUFD) in these couples. Our findings suggest that this is a matter for further study as it will greatly influence the approach to counseling and managing consanguineous couples with pregnancy loss.

Histaminergic system of the lateral septum in the modulation of anxiety-like behaviour in rats.

The central histaminergic system is known to have modulatory influence on anxiety-related behaviour both in animals and humans through histamine H1 and/or H2 receptors. In the present study, the effects of intra-lateral septal microinjections of histaminergic agents on anxiety-related behaviours in male Wistar rats have been investigated. As a model of anxiety, the elevated plus-maze which is a useful test to investigate the effects of anxiogenic or anxiolytic drugs in rodents was used. Intra-lateral septal administration of histamine (0.5 and 1 microg/rat) decreased the percentage of open arm entries and open arm time but not locomotor activity, showing an anxiogenic response. The intra-lateral septal injections of different doses of the histamine H1 receptor antagonist, pyrilamine (5, 10 and 20 microg/rat) or the histamine H2 receptor antagonist, ranitidine (5, 10 and 20 microg/rat) could not significantly alter the anxiety-like parameters in the plus-maze test. However, intra-lateral septal injections of different doses of pyrilamine (10 and 20 microg/rat) or ranitidine (10 and 20 microg/rat) significantly reversed histamine (1 microg/rat)-induced anxiogenic effect. The results may indicate that the histaminergic system of lateral septum modulate anxiety-like behaviour through histamine H1 and H2 receptors.

GABA and histamine interaction in the basolateral amygdala of rats in the plus-maze test of anxiety-like behaviors.

In the present study, we have investigated the effects and the interaction of the GABAergic and histaminergic systems in the basolateral amygdala (BLA) of rats using the plus-maze test of anxiety-like behaviors. Unilateral injection of different doses of muscimol (GABA(A) receptor selective agonist; 0.01, 0.05 and 0.1 microg/rat) into the BLA (intra-BLA) increased the percentage of open arm time (%OAT) and open arm entries (%OAE) at the doses of 0.05 and 0.1 microg/rat that are representative of an anxiolytic response. Intra-BLA injection of bicuculline (GABA(A) receptor selective antagonist; 0.05, 0.1 and 0.5 microg/rat) decreased %OAT and %OAE at the doses of 0.1 and 0.5 microg/rat showing an anxiogenic-like effect. Intra-BLA administration of histamine (0.05, 0.1 and 0.5 microg/rat) also showed anxiogenic-like effects at the doses of 0.1 and 0.5 microg/rat while intra-BLA administration of pyrilamine (an H1 receptor selective antagonist; 5, 10 and 20 microg/rat) induced anxiolytic effects at the dose of 20 microg/rat. Coadministration of histamine (0.1 microg/rat) with muscimol reversed the anxiolytic effect of muscimol at the dose of 0.1 microg/rat while coadministration of histamine (0.1 microg/rat) with bicuculline increased the anxiogenic effect of bicuculline at the dose of 0.05 microg/rat. On the other hand, coadministration of pyrilamine (10 microg/rat) with bicuculline decreased anxiety-like behaviors of bicuculline at the dose of 0.5 microg/rat while pyrilamine could not affect the anxiolytic effect of muscimol. In conclusion, it seems that both GABAergic and histaminergic systems not only play a part in the modulation of anxiety-like behaviors in the BLA of rats but may also have opposite effects in this brain region.

Repeated pre-exposure to morphine into the ventral pallidum enhances morphine-induced place preference: involvement of dopaminergic and opioidergic mechanisms.

In the present study, the effect of repeated administration of morphine into the ventral pallidum (intra-VP) on the conditioned place preference (CPP) induced by systemic morphine injection was investigated in male Wistar rats. Subcutaneous (s.c.) administration of morphine (2.5, 5 and 7.5mg/kg), during conditioning, induced conditioned place preference (CPP). The maximum response was obtained with 5mg/kg of morphine. Lower dose of morphine (0.5mg/kg) did not induce CPP, but in the animals which had previously, received 3 days intra-VP repeated injections of morphine (3 or 5microg/rat) followed by 5 days free of the drug, elicited a significant CPP. Moreover, 3 days intraperitoneal (i.p.) pretreatment with different doses of naloxone (0.5, 1 and 2mg/kg), SCH 23390 (0.012, 0.025 and 0.05mg/kg) or sulpiride (6.2, 12.5 and 25mg/kg) in combination with repeated injections of morphine (5microg/rat), blocked the opioid response on the acquisition of morphine (0.5mg/kg) CPP. On the other hand, our results showed that 3 days single repeated administration of different doses of naloxone (0.5, 1 or 2mg/kg, i.p.), SCH 23390 but not sulpiride followed by 5 days free of the drug, significantly decreased the acquisition of morphine (0.5mg/kg) CPP and also induced place aversion. Furthermore, the drugs' injections had no effect on locomotor activity on the testing phase of CPP. It is concluded that repeated intra-VP injections of morphine induces behavioral sensitization, which may be due to the opioidrgic and/or dopaminergic mechanism(s).

Repeated administration of dopaminergic agents in the nucleus accumbens and morphine-induced place preference.

In the present study, the effects of repeated intra nucleus accumbens (intra-NAc) injections of dopamine receptor agents on morphine-induced conditioned place preference (CPP) in rats were investigated by using an unbiased 3-days schedule of place conditioning design. The animals receiving once daily subcutaneous (s.c.) injections of morphine (0.5-7.5mg/kg) or saline (1.0 ml/kg, s.c.) showed a significant place preference in a dose-dependent manner. The maximum response was observed with 5mg/kg of the opioid. Three days intra-NAc injections of apomorphine (0.5 and 1 microg/rat) followed by 5 days free of the drug, increased or decreased, respectively CPP induced by the lower dose of morphine (0.5mg/kg, s.c.). Morphine-induced CPP was also significantly increased in the animals that had previously received the 3-days intra-NAc injections of SKF 38393 (4 and 8 microg/rat) or quinpirole (2 and 4 microg/rat, intra-NAc). The CPP induced by a higher dose of morphine (5mg/kg, s.c.) was significantly decreased in the animals that had previously received the 3-days SCH 23390 (0.005 and 0.01 microg/rat; intra-NAc). On the other hand, the CPP induced by morphine (5mg/kg, s.c.) was significantly increased in the animals that had previously received the 3-days sulpiride administration (5 microg/rat, intra-NAc). The 3-days administration of apomorphine, SKF 38393 or quinpirole, but not SCH 23390 and sulpiride reduced the locomotor activity in the test session. It is concluded that repeated injections of dopamine receptors agents followed by 5 days free of the drugs in the NAc can affect morphine reward.

Histaminergic receptors of medial septum and conditioned place preference: D1 dopamine receptor mechanism.

In the present study, the effects of intra-medial septum injections of histamine and/or the histamine H1 or H2 receptor antagonists on the acquisition of conditioned place preference (CPP) in male Wistar rats have been investigated. Our data showed that the conditioning treatments with intra-medial septum injection of different doses of histamine (0.5-15 microg/rat) induced a significant CPP for the drug-associated place. Using a 3-day schedule of conditioning, it was found that the histamine H1 receptor antagonist, pyrilamine (10 and 15 microg/rat, intra-medial septum) also induced a significant place preference. In addition, pyrilamine inhibited the histamine (7.5 microg/rat)-induced place preference. Intra-medial septum administration of the histamine H2 receptor antagonist, ranitidine (5-15 microg/rat) alone or in combination with histamine did not produce a significant place preference or place aversion. On the other hand, intra-medial septum administration of the dopamine D1 receptor antagonist, SCH 233390 (0.5, 0.75 and 1 microg/rat) inhibited the histamine (7.5 microg/rat) or pyrilamine (15 microg/rat)-induced place preference in a dose-dependent manner, but no effect was observed for the dopamine D2 receptor antagonist, sulpiride on the histamine or pyrilamine response. The administration of histamine (2.5-15 microg/rat) or pyrilamine (10 and 15 microg/rat) during acquisition increased locomotor activity of the animals on the testing days. The results suggest that histaminergic receptors of the medial septum may be involved in CPP and thus it is postulated that dopamine D1 receptors may play an important role in this effect.

The effects of histaminergic agents in the ventral hippocampus of rats in the plus-maze test of anxiety-like behaviours.

It has been suggested that histamine have modulatory influence on anxiety-related behaviours both in animals and humans. Ventral hippocampus (VHC) may also be an important brain site in the modulation of fear or anxiety. In the present study, the effects of histaminergic agents on anxiety-related behaviours in the rats, using plus-maze test has been investigated. Intra-VHC administration of histamine (2.5, 5 and 7.5 microg/rat) decreased %OAT and %OAE but not locomotor activity, showing an anxiogenic response. Pretreatment of animals with either pyrilamine, a H1 receptor antagonist (10 microg/rat), or ranitidine, a H2 receptor antagonist (10 microg/rat) reverse anxiogenic response of histamine (2.5, 5 and 7.5 microg/rat). However, intra-VHC microinjection of higher doses of pyrilamine (40 microg/rat) or ranitidine (20 and 40 microg/rat) alone increased anxiety-like behaviours in rats. Our results showed that histamine may modulate anxiety-like behaviours via H1 and H2 receptors in the ventral hippocampus of the rats.

The influence of central administration of dopaminergic and cholinergic agents on morphine-induced amnesia in morphine-sensitized mice.

In the present study, effects of intracerebroventricular (i.c.v.) injections of dopaminergic and cholinergic agents on morphine-induced amnesia in morphine-sensitized mice were investigated by using a one-trial passive avoidance task. Amnesia induced by pre-training morphine was significantly reversed in morphine-sensitized mice, which had previously received once daily injections of morphine (20 and 30 mg/kg, s.c.) for 3 days. Three daily injections of SKF 38393 (1, 2 and 4 g/mouse, i.c.v.) or SCH 23390 (0.25, 0.5, 0.75 and 1 g/mouse, i.c.v.) before morphine, and during morphine-sensitization, decreased and increased the amnesia induced by pre-training morphine respectively. Three daily injections of quinpirole (0.3, 1 and 3 g/mouse, i.c.v.) or sulpiride (0.03, 0.1, 0.3 and 1 g/mouse, i.c.v.) before morphine, also decreased and increased the amnesia induced by pre-training morphine respectively. Morphine-sensitized mice received similar injections of cholinergic agents. Three daily injections of physostigmine (1, 3 and 5 g/mouse, i.c.v.) or atropine (1, 4 and 7 g/mouse, i.c.v.) before morphine, and during morphine-sensitization, decreased and increased the amnesia induced by pre-training morphine respectively. Three daily injections of nicotine (0.75, 1 and 2 g/mouse, i.c.v.) or mecamylamine (1, 3 and 6 g/mouse, i.c.v.) before morphine, also decreased and increased the amnesia induced by pre-training morphine respectively. The results suggest that morphine sensitization affects the impairment of memory formation and thus it is postulated that central dopaminergic and cholinergic systems may play an important role in this effect.

The effects of histaminergic agents in the dorsal hippocampus of rats in the elevated plus-maze test of anxiety.

High levels of histamine are found in the hippocampus. The central histamine system is involved in many physiological behavioural processes including anxiety-related behaviours both in animals and humans. In the present study, we investigated the effects of intra-hippocampal CA1 (intra-CA1) microinjection of histaminergic agents on anxiety-related behaviours in rats, using elevated plus-maze test of anxiety. Intra-CA1 administration of histamine (at the dose of 10 microg/rat) increased open arm time (%OAT) and open arm entry (%OAE) but not locomotor activity, thus showing an anxiolytic response. Intra-CA1 microinjection of pyrilamine (H1 receptor antagonist; at the doses of 10, 20 and 40 microg/rat) in combination with histamine (10 microg/rat) showed a decrease in the %OAT and %OAE. Higher dose of the antagonist (40 microg/rat) by itself increased both %OAT and %OAE, but not locomotor activity, indicating an anxiolytic effect. Intra-CA1 microinjection of ranitidine (H2 receptor antagonist), at the doses of 10, 20 and 40 microg/rat, also reduced the histamine response. Furthermore, the H2 receptor antagonist by itself reduced %OAT and %OAE without affecting locomotor activity. The results may indicate an anxiogenic effect for the antagonist. Our results showed that histamine may modulate anxiety via H1 and H2 receptors in the CA1 region of hippocampus of the rat.

Anxiolytic effect of noscapine in mice.

The anxiety-related effects of noscapine were investigated using male Balb-c mice. Since noscapine-induced locomotion may alter the animals' activity level in the dark-light model, the anxiety-related effects of noscapine were studied at doses with no effect on locomotion (0.1, 0.2, 0.3, 0.4, 0.5, 0.8, 1, 1.5 and 2 mg/kg). The parameter measured in dark-light model was the time spent in lit compartment. Intraperitoneal administration of noscapine (0.1-0.5 mg/kg) did not produce a significant effect on the time spent in the light, whereas higher doses (0.8, 1, 1.5 and 2 mg/kg) increased it significantly, implying an anxiolytic effect.

Involvement of the ventral tegmental area (VTA) in morphine-induced memory retention in morphine-sensitized rats.

In the present study, the effects of intra-ventral tegmental area (VTA) injections of morphine on memory retention of a one-trial passive avoidance task have been investigated in morphine-sensitized rats. Retrieval was examined 24h after training and used as memory retention. Sensitization was obtained by subcutaneous (s.c.) injections of morphine, once daily for 3 and 5 days free of the opioid before training. Post-training administration of the both systemic (2.5, 5 and 7.5mg/kg, s.c.) and intra-VTA (5 and 7.5microg/rat) of morphine, dose-dependently decreased memory retention. The response induced by post-training administration of intra-VTA morphine (7.5microg/rat) was significantly reversed in morphine-sensitized rats. The inhibition of morphine-induced amnesia in morphine-sensitized rats was decreased by once daily injections of naloxone (0.5, 1 and 2mg/kg, s.c.), SCH 23390 (0.025, 0.05 and 0.1mg/kg, s.c.) or sulpiride (25, 50 and 100mg/kg, s.c.), during the sensitization. The results suggest that VTA has an important role in morphine-induced amnesia and morphine sensitization affects this process through opioid and dopamine receptors.

Role of the cholinergic system in the rat basolateral amygdala on morphine-induced conditioned place preference.

The effects of intra-basolateral amygdala (intra-BLA) injections of physostigmine, atropine, nicotine and/or mecamylamine on morphine-induced conditioned place preference (CPP) in rats was investigated by using an unbiased 3-day schedule of place conditioning design. Animals that received 3 daily injections of morphine (0.5-10 mg/kg) subcutaneously (s.c.) or saline (1.0 ml/kg, s.c.) showed a significant preference for compartment paired with morphine. The maximum response was observed with 7.5 mg/kg of the opioid. Administration of the anticholinesterase drug, physostigmine (1, 3 and 5 microg/rat) with an ineffective dose of morphine (0.5 mg/kg) elicited a significant CPP. Injections of antimuscarinic receptor agent, atropine (1, 4 and 7 microg/rat) dose-dependently inhibited the morphine (7.5 mg/kg)-induced place preference. The injections of nicotine (0.75, 1 and 2 microg/rat) potentiated the morphine (0.5 mg/kg)-induced place preference, while the nicotinic receptor antagonist, mecamylamine (1, 3 and 6 microg/rat) dose-dependently inhibited the morphine (7.5 mg/kg)-induced place preference. Furthermore, administration of atropine (7 microg/rat) but not mecamylamine (6 microg/rat) reduced the response induced by different doses of physostigmine plus morphine. Moreover, mecamylamine (6 microg/rat) but not atropine (7 microg/rat) reduced the response induced by different doses of nicotine plus morphine. It is concluded that the muscarinic and nicotinic receptor mechanisms in the BLA may be involved in the acquisition of morphine-induced place preference.

Intracerebroventricular effects of histaminergic agents on morphine-induced anxiolysis in the elevated plus-maze in rats.

Some reports indicate that morphine can induce anxiolytic effects both in animal and in man. It has also been reported that histaminergic system can interfere with some pharmacological effects of morphine. The effects of histaminergic agents on morphine-induced anxiolysis in rats, using elevated plus-maze were investigated in the present study. Intraperitoneal injection of morphine (3, 6 and 9 mg/kg) induced antianxiety effects. Intracerebroventricular administration of histamine at the doses of (5, 10 and 20 microg/rat) also increased anxiety-related behaviours. Intracerebroventricular injection of pyrilamine, a H1 receptor antagonist (25, 50 and 100 microg/rat), increased anxiety whereas injection of ranitidine, a H2 receptor antagonist (5, 10 and 20 microg/rat) at the same site, decreased anxiety. Therefore, it seems that histamine induces anxiogenic response through activation of H2 receptors, while the response of H1 blocker may be due to release of histamine. We also evaluated the interactions between morphine and histaminergic agents. Our data show that histamine (10 microg/rat), pyrilamine (50 microg/rat) and ranitidine (5 microg/rat) did not alter the response induced by different doses of morphine (3, 6 and 9 mg/kg). Similarly, a single dose of morphine did not alter the response induced by different doses of histamine (5, 10 and 20 microg/rat), pyrilamine (25, 50 and 100 microg/rat) or ranitidine (5, 10 and 20 microg/rat). In conclusion, the histaminergic system plays an important role in the modulation of anxiety, although in our experiments, no interaction was found between the effects of histaminergic agents and morphine on anxiety-related indices in the elevated plus-maze. This may imply that morphine-induced anxiolysis probably is independent of the histaminergic system.

Prenatal Screening for Aneuploidies Using QF-PCR and Karyotyping: A Comprehensive Study in Iranian Population.

BACKGROUND: We have investigated the efficacy of QF-PCR for the prenatal recognition of common aneuploidy and compared our findings with cytogenetic results in our laboratories. METHODS: A total of 4058 prenatal samples (4031 amniotic fluid and 27 chorionic villous samples) were analyzed by QF-PCR using several selected STR markers together with amelogenin. Results were compared to those obtained by conventional cytogenetic analysis. RESULTS: We detected 139 (3.42%) numerical abnormalities in our subjects by QF-PCR. Concordant QF-PCR and karyotype results were obtained in 4001 (98.59%) of the samples. An abnormal karyotype associated with adverse clinical outcome undetected by QF-PCR was found in 16.66% (n = 28) of samples. Using QF-PCR alone, we were able to detect abnormalities in 98.59% of all referred families; however the karyotyping results improved the detection rate to 99.85% of the referred cases. Individuals with neonatal screening result with 1:10 risk ratio showed 11.29% abnormal karyotype while this number was 2.16% in mothers with risk ratio of 1:250 or less. CONCLUSION: In countries where large scale conventional cytogenetic is hampered by its high cost and lack of technical expertise, QF-PCR may be used as the first line of screening for detection of chromosomal abnormalities. We also recommend QF-PCR for all the families that are seeking prenatal diagnosis of single gene disorders aneuploidies screening to be added to their work up.

Adrenoceptor mechanisms underlying imipramine-induced memory deficits in rats.

The post-training administration of tricyclic antidepressant imipramine impairs memory consolidation in the passive avoidance task. The present study investigated the effects of intrahippocampal (i.h.) injection of adrenoceptor agents on imipramine-induced (2-8 microg/rat) amnesia. The administration of the alpha1-adrenoceptor agonist phenylephrine (0.05 microg/rat) and the alpha1-adrenceptor antagonist prazosin (0.5 microg/rat) did not alter the effect of imipramine. The lower doses of phenylephrine (0.005 and 0.015 microg/rat) impaired, while the higher dose of the drug (0.025 and 0.05 microg/rat) improved retention. The effect of phenylephrine was not altered by prazosin (0.5 and 1 microg/rat) pretreatment, although prazosin alone decreased retention latencies. The alpha2-adrenoceptor antagonist yohimbine (0.5 and 1 microg/rat) decreased the response induced by imipramine. However, the alpha2-adrenoceptor agonist clonidine (0.08 microg/rat) did not alter the effect of the drug. Clonidine (0.15 and 0.3 microg/rat) by itself decreased, while yohimbine (1 and 2 microg/rat) increased retention latencies. Yohimbine pretreatment attenuated the effect of clonidine. It is concluded that alpha2-adrenoceptor mechanism(s) may be involved in imipramine-induced impairment of memory.

Cross-tolerance between morphine- and nicotine-induced conditioned place preference in mice.

The acquisition of morphine and nicotine conditioned place preference (CPP) and cross-tolerance between the response of two drugs was studied in mice. A biased CPP paradigm was used to study the effect of the agents. Morphine (5 mg/kg) and nicotine (1 mg/kg) induced CPP. Naloxone (0.5, 1 and 2 mg/kg), but not mecamylamine (0.025, 0.05 and 0.1 mg/kg), induced conditioned place aversion (CPA). Both antagonists reversed CPP induced by morphine and nicotine. Administration of one daily dose of morphine (12.5, 25 or 50 mg/kg) for 3 days or nicotine (0.5, 1 or 2 mg/kg) three times a day for 12 days, in order to develop tolerance to the drugs, reduced the conditioning induced by morphine (5 mg/kg) or nicotine (1 mg/kg). CPA-induced by naloxone was reduced in animals, which were rendered tolerant to morphine (50 mg/kg) or nicotine (2 mg/kg). Mecamylamine, however, which did not induce any response in the nontolerant mice, elicited CPP in the tolerant animals. It is concluded that there may be a cross-tolerance between morphine- and nicotine-induced CPP.

Involvement of the nucleus accumbens shell dopaminergic system in prelimbic NMDA-induced anxiolytic-like behaviors.

BACKGROUND: Nucleus accumbens (NAc) and prefrontal cortex (PFC) dopaminergic and glutamatergic systems are involved in fear/anxiety-related behaviors; meanwhile NAc dopaminergic system activity is mediated by PFC via NAc glutamatergic projections. This study has investigated the involvement of NAc shell dopaminergic system in prelimbic NMDA-induced anxiolytic-like behaviors. METHOD: Elevated plus-maze apparatus was employed to test parameters of anxiety-like behaviors in male Wistar rats. RESULTS: Unilateral intra-prelimbic injection of NMDA (0.9 µg/µl) but not D-AP7 (NMDA receptor antagonist; 0.25, 0.5 and 1 µg/µl) induced anxiolytic-like behaviors which was blocked by D-AP7. Moreover, unilateral infusion of SCH23390 (dopamine D1 receptor antagonist; 0.25, 0.5 and 1 µg/µl) and quinpirole (dopamine D2 receptor agonist; 0.125, 0.25 and 0.5 µg/µl) into the left NAc shell, did not alter anxiety-like behaviors. However, injection of SKF38393 (dopamine D1 receptor agonist; 3 µg/µl) and sulpiride (dopamine D2 receptor antagonist; 0.4 and 0.6 µg/µl) into the left NAc shell, likewise induced anxiolytic-like behaviors which were blocked by SCH23390 (0.25 µg/µl) and SKF96365 (Ca-channel blocker; 0.125 µg/µl)/SCH23390 (0.25 µg/µl), respectively. Furthermore, infusion of the subthreshold dose of SCH23390 (0.25 µg/µl) or quinpirole (0.25 µg/µl) into the left NAc shell, reduced while did not alter intra-prelimbic NMDA-induced anxiolytic-like behaviors, respectively. In addition, intra-NAc shell administration of the subthreshold dose of SKF38393 (1 µg/µl) or sulpiride (0.2 µg/µl), potentiated the lower dose response, while decreased the higher dose intra-left prelimbic NMDA response. CONCLUSION: Our results suggested a modulatory effect of the NAc shell dopaminergic system on prelimbic NMDA-induced anxiolytic-like behaviors.